204 related articles for article (PubMed ID: 30625263)
1. Clinical aspects and treatments for pediatric inflammatory bowel disease.
Moon JS
Intest Res; 2019 Jan; 17(1):17-23. PubMed ID: 30625263
[TBL] [Abstract][Full Text] [Related]
2. Clinical Aspects and Treatments for Pediatric Inflammatory Bowel Diseases.
Moon JS
Pediatr Gastroenterol Hepatol Nutr; 2019 Jan; 22(1):50-56. PubMed ID: 30671373
[TBL] [Abstract][Full Text] [Related]
3. Allergic and Immunologic Perspectives of Inflammatory Bowel Disease.
Clarke K; Chintanaboina J
Clin Rev Allergy Immunol; 2019 Oct; 57(2):179-193. PubMed ID: 29754190
[TBL] [Abstract][Full Text] [Related]
4. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
5. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
6. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease.
Carman N; Mack DR; Benchimol EI
Curr Gastroenterol Rep; 2018 Apr; 20(5):18. PubMed ID: 29623442
[TBL] [Abstract][Full Text] [Related]
8. Positioning Biologic Therapies in the Management of Pediatric Inflammatory Bowel Disease.
Breton J; Kastl A; Conrad MA; Baldassano RN
Gastroenterol Hepatol (N Y); 2020 Aug; 16(8):400-414. PubMed ID: 34035746
[TBL] [Abstract][Full Text] [Related]
9. Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
Greuter T; Bertoldo F; Rechner R; Straumann A; Biedermann L; Zeitz J; Misselwitz B; Scharl M; Rogler G; Safroneeva E; Ali RAR; Braegger C; Heyland K; Mueller P; Nydegger A; Petit LM; Schibli S; Furlano RI; Spalinger J; Schäppi M; Zamora S; Froehlich F; Herzog D; Schoepfer AM; Vavricka SR;
J Pediatr Gastroenterol Nutr; 2017 Aug; 65(2):200-206. PubMed ID: 27801751
[TBL] [Abstract][Full Text] [Related]
10. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
11. Current issues of pediatric inflammatory bowel disease in Korea.
Oh SH; Kim KM
Korean J Pediatr; 2014 Nov; 57(11):465-71. PubMed ID: 25550700
[TBL] [Abstract][Full Text] [Related]
12. Current concepts in pediatric inflammatory bowel disease; IL10/IL10R colitis as a model disease.
Almana Y; Mohammed R
Int J Pediatr Adolesc Med; 2019 Mar; 6(1):1-5. PubMed ID: 31304220
[TBL] [Abstract][Full Text] [Related]
13. Pediatric inflammatory bowel disease: clinical and therapeutic aspects.
Kugathasan S
Curr Opin Gastroenterol; 2001 Jul; 17(4):350-5. PubMed ID: 17031182
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort.
Tremelling M; Waller S; Bredin F; Greenfield S; Parkes M
Inflamm Bowel Dis; 2006 Mar; 12(3):178-84. PubMed ID: 16534418
[TBL] [Abstract][Full Text] [Related]
15. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
16. Development of inflammatory bowel disease during anti-TNF-α therapy for inflammatory rheumatic disease: a nationwide series.
Toussirot É; Houvenagel É; Goëb V; Fouache D; Martin A; Le Dantec P; Dernis E; Wendling D; Ansemant T; Berthelot JM; Bader-Meunier B; Kantelip B;
Joint Bone Spine; 2012 Oct; 79(5):457-63. PubMed ID: 22088934
[TBL] [Abstract][Full Text] [Related]
17. An Update on Inflammatory Bowel Disease.
Sairenji T; Collins KL; Evans DV
Prim Care; 2017 Dec; 44(4):673-692. PubMed ID: 29132528
[TBL] [Abstract][Full Text] [Related]
18. Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.
de Bie CI; Escher JC; de Ridder L
Inflamm Bowel Dis; 2012 May; 18(5):985-1002. PubMed ID: 21936033
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
20. Monogenic diseases associated with intestinal inflammation: implications for the understanding of inflammatory bowel disease.
Uhlig HH
Gut; 2013 Dec; 62(12):1795-805. PubMed ID: 24203055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
